Johnson & Johnson (NYSE:JNJ) Shares Bought by Arbor Capital Management Inc. ADV

Arbor Capital Management Inc. ADV raised its holdings in Johnson & Johnson (NYSE:JNJ) by 4.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,382 shares of the company’s stock after acquiring an additional 494 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Arbor Capital Management Inc. ADV’s portfolio, making the stock its 19th biggest holding. Arbor Capital Management Inc. ADV’s holdings in Johnson & Johnson were worth $1,722,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of JNJ. Swedbank AB lifted its stake in Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after buying an additional 329,473 shares in the last quarter. United Bank lifted its stake in Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after buying an additional 202 shares in the last quarter. Seizert Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 1.0% in the 3rd quarter. Seizert Capital Partners LLC now owns 244,057 shares of the company’s stock valued at $39,552,000 after purchasing an additional 2,441 shares during the period. Finally, Accredited Investors Inc. lifted its position in shares of Johnson & Johnson by 4.0% in the third quarter. Accredited Investors Inc. now owns 7,901 shares of the company’s stock worth $1,280,000 after purchasing an additional 301 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Bank of America boosted their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Trading Down 0.0 %

Johnson & Johnson stock opened at $162.94 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business’s 50-day simple moving average is $154.98 and its 200-day simple moving average is $156.27. The firm has a market capitalization of $392.29 billion, a PE ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.